Form 8.3 - Udg Healthcare Plc

 
TIDMUDG 
 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

 
Name of person dealing (Note 1)       State Street Global Advisors & 
                                       Affiliates 
------------------------------------  ------------------------------ 
Company dealt in                      UDG Healthcare plc 
------------------------------------  ------------------------------ 
Class of relevant security to         EUR0.05 ordinary shares 
 which 
 the dealings being disclosed relate 
 (Note 2) 
------------------------------------  ------------------------------ 
Date of dealing                       17th June 2021 
------------------------------------  ------------------------------ 
 
 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 
                                    Long             Short 
---------------------------  -------------------  ----------- 
                              Number      (%)     Number  (%) 
---------------------------  ---------  --------  ------  --- 
(1) Relevant securities      2,828,435  1.12270% 
---------------------------  ---------  --------  ------  --- 
(2) Derivatives (other 
 than options)                     N/A 
---------------------------  ---------  --------  ------  --- 
(3) Options and agreements 
 to 
 purchase/sell                     N/A 
---------------------------  ---------  --------  ------  --- 
Total                        2,828,435  1.12270% 
---------------------------  ---------  --------  ------  --- 
 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 
Class of relevant security:     Long         Short 
---------------------------  -----------  ----------- 
                             Number  (%)  Number  (%) 
---------------------------  ------  ---  ------  --- 
(1) Relevant securities       N/A 
---------------------------  ------  ---  ------  --- 
(2) Derivatives (other        N/A 
 than options) 
---------------------------  ------  ---  ------  --- 
(3) Options and agreements    N/A 
 to purchase/sell 
---------------------------  ------  ---  ------  --- 
Total                         N/A 
---------------------------  ------  ---  ------  --- 
 

3. DEALINGS (Note 4)

(a) Purchases and sales

 
                                               Price per unit (Note 
Purchase/sale   Number of relevant securities           5) 
--------------  -----------------------------  -------------------- 
     Sale                              10,950                 10.50 
--------------  -----------------------------  -------------------- 
 

(b) Derivatives transactions (other than options transactions)

 
Product name,  Nature of transaction  Number of relevant securities  Price per 
 e.g. CFD       (Note 6)               (Note 7)                       unit 
                                                                      (Note 5) 
-------------  ---------------------  -----------------------------  --------- 
N/A 
-------------  ---------------------  -----------------------------  --------- 
 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

 
Product name,  Writing,       Number of            Exercise  Type, e.g.  Expiry  Option money 
 e.g. call      selling,       securities to        price     American,   date    paid/received 
 option         purchasing     which                          European            per unit 
                varying etc.   the option relates             etc.                (Note 5) 
                               (Note 7) 
-------------  -------------  -------------------  --------  ----------  ------  -------------- 
N/A 
-------------  -------------  -------------------  --------  ----------  ------  -------------- 
 

(ii) Exercising

 
Product name,      Number of securities  Exercise price per 
 e.g. call option                           unit (Note 5) 
-----------------  --------------------  ------------------ 
N/A 
-----------------  --------------------  ------------------ 
 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 
Nature of transaction  Details      Price per unit 
 (Note 8)                        (if applicable) (Note 
                                          5) 
---------------------  -------  ---------------------- 
N/A 
---------------------  -------  ---------------------- 
 

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 
Full details of any agreement, arrangement or understanding between 
 the person disclosing and any other person relating to the voting 
 rights of any relevant securities under any option referred to 
 on this form or relating to the voting rights or future acquisition 
 or disposal of any relevant securities to which any derivative 
 referred to on this form is referenced. If none, this should be 
 stated. 
-------------------------------------------------------------------- 
N/A 
-------------------------------------------------------------------- 
 
 
Is a Supplemental Form 8 attached? 
 (Note 9)                                           NO 
--------------------------------------------  -------------- 
Date of disclosure                            18th June 2021 
--------------------------------------------  -------------- 
Contact name                                  Lionel Colaco 
--------------------------------------------  -------------- 
Telephone number                                020 33956098 
--------------------------------------------  -------------- 
If a connected EFM, name of offeree/offeror   N/A 
 with which connected 
--------------------------------------------  -------------- 
If a connected EFM, state nature              N/A 
 of connection (Note 10) 
--------------------------------------------  -------------- 
 
 
 

(END) Dow Jones Newswires

June 18, 2021 09:58 ET (13:58 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.